. Author manuscript; available in PMC: 2014 Feb 27.

Published in final edited form as: Sci Transl Med. 2013 Feb 27;5(174):10.1126/scitranslmed.3004812. doi: 10.1126/scitranslmed.3004812

Table 1.

Subject characteristics.

	Mild Asthma	Severe Asthma
No. of subjects	11	11
Clinical data
Age (years)	30.6±10.2 (21–54)	41.5±11.8 (26–60)^*
Gender (M:F)	3:8	2:9
Race (% white)	45	55
Ethnicity (% Hispanic)	9	18
Inhaled corticosteroids (Fluticasone equivalent, μg per day)	152.73±143.74 (0–360)	1085.46±303.06 (640–1760)^*
Oral corticosteroids (%)	0	0
Long Acting Beta-Agonist (%)	0	100^*
Leukotriene Antagonists (%)	0	18^*
Omalizumab (%)	0	18^*
ACQ Score	1.18±0.58 (0.43–2.43)	2.52±0.64 (1.57–3.57)^*
FEV1 (L)	3.25±0.39 (2.74–3.93)	2.14±0.57 (1.27–3.35)^*
FEV1 (% predicted)	96.8±8.5 (82–106)	71.9±17.3 (45–101)^*

Definition of abbrevations: ACQ = Asthma Control Questionnaire.

Results are expressed as mean ± SD (range)

P < 0.05 when compared with subjects with mild asthma.